Top Key Companies for Hereditary Angioedema Treatment Market: Pharming Group NV, CSL Behring, BIOCRYST PHARMACEUTICALS,INC, Attune Pharmaceuticals, Shire plc., Adverum, lonis Pharmaceuticals,Inc, Arrowhead Pharmaceuticals,Inc..
Global Hereditary Angioedema Treatment Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Hereditary Angioedema Treatment Market Overview And Scope:
The Global Hereditary Angioedema Treatment Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Hereditary Angioedema Treatment utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Global Hereditary Angioedema Treatment Market Segmentation
By Type, Hereditary Angioedema Treatment market has been segmented into:
C-1 Esterase Inhibitors
Bradykynin Receptor Antagonist
Kallikrein Inhibitors
By Application, Hereditary Angioedema Treatment market has been segmented into:
Prophylaxis
Treatment
Regional Analysis of Hereditary Angioedema Treatment Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Hereditary Angioedema Treatment Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Hereditary Angioedema Treatment market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Hereditary Angioedema Treatment market.
Top Key Companies Covered in Hereditary Angioedema Treatment market are:
Pharming Group NV
CSL Behring
BIOCRYST PHARMACEUTICALS
INC
Attune Pharmaceuticals
Shire plc.
Adverum
lonis Pharmaceuticals
Inc
Arrowhead Pharmaceuticals
Inc.
Key Questions answered in the Hereditary Angioedema Treatment Market Report:
1. What is the expected Hereditary Angioedema Treatment Market size during the forecast period, 2025-2032?
2. Which region is the largest market for the Hereditary Angioedema Treatment Market?
3. What is the expected future scenario and the revenue generated by different regions and countries in the Hereditary Angioedema Treatment Market, such as North America, Europe, AsiaPacific & Japan, China, U.K., South America, and Middle East and Africa?
4. What is the competitive strength of the key players in the Hereditary Angioedema Treatment Market on the basis of the analysis of their recent developments, product offerings, and regional presence?
5. Where do the key Hereditary Angioedema Treatment companies lie in their competitive benchmarking compared to the factors of market coverage and market potential?
6. How are the adoption scenario, related opportunities, and challenges impacting the Hereditary Angioedema Treatment Markets?
7. How is the funding and investment landscape in the Hereditary Angioedema Treatment Market?
8. Which are the leading consortiums and associations in the Hereditary Angioedema Treatment Market, and what is their role in the market?
Research Methodology for Hereditary Angioedema Treatment Market Report:
The report presents a detailed assessment of the Hereditary Angioedema Treatment Market, along with qualitative inputs and insights from Company. This research study involved the extensive use of both primary and secondary sources.Various factors affecting the industry were studied to identify the segmentation types; industry trends; key players; competitive landscape of different products and services provided by separate market players;key market dynamics, such as drivers, restraints, opportunities, challenges, and industry trends; and key player strategies. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights.Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Hereditary Angioedema Treatment Market by Type
5.1 Hereditary Angioedema Treatment Market Overview Snapshot and Growth Engine
5.2 Hereditary Angioedema Treatment Market Overview
5.3 C-1 Esterase Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 C-1 Esterase Inhibitors: Geographic Segmentation
5.4 Bradykynin Receptor Antagonist
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Bradykynin Receptor Antagonist: Geographic Segmentation
5.5 Kallikrein Inhibitors
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Kallikrein Inhibitors: Geographic Segmentation
Chapter 6: Hereditary Angioedema Treatment Market by Application
6.1 Hereditary Angioedema Treatment Market Overview Snapshot and Growth Engine
6.2 Hereditary Angioedema Treatment Market Overview
6.3 Prophylaxis
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Prophylaxis: Geographic Segmentation
6.4 Treatment
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Treatment: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Hereditary Angioedema Treatment Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Hereditary Angioedema Treatment Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Hereditary Angioedema Treatment Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 PHARMING GROUP NV
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 CSL BEHRING
7.4 BIOCRYST PHARMACEUTICALS
7.5 INC
7.6 ATTUNE PHARMACEUTICALS
7.7 SHIRE PLC.
7.8 ADVERUM
7.9 LONIS PHARMACEUTICALS
7.10 INC
7.11 ARROWHEAD PHARMACEUTICALS
7.12 INC.
Chapter 8: Global Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 C-1 Esterase Inhibitors
8.2.2 Bradykynin Receptor Antagonist
8.2.3 Kallikrein Inhibitors
8.3 Historic and Forecasted Market Size By Application
8.3.1 Prophylaxis
8.3.2 Treatment
Chapter 9: North America Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 C-1 Esterase Inhibitors
9.4.2 Bradykynin Receptor Antagonist
9.4.3 Kallikrein Inhibitors
9.5 Historic and Forecasted Market Size By Application
9.5.1 Prophylaxis
9.5.2 Treatment
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 C-1 Esterase Inhibitors
10.4.2 Bradykynin Receptor Antagonist
10.4.3 Kallikrein Inhibitors
10.5 Historic and Forecasted Market Size By Application
10.5.1 Prophylaxis
10.5.2 Treatment
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 C-1 Esterase Inhibitors
11.4.2 Bradykynin Receptor Antagonist
11.4.3 Kallikrein Inhibitors
11.5 Historic and Forecasted Market Size By Application
11.5.1 Prophylaxis
11.5.2 Treatment
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 C-1 Esterase Inhibitors
12.4.2 Bradykynin Receptor Antagonist
12.4.3 Kallikrein Inhibitors
12.5 Historic and Forecasted Market Size By Application
12.5.1 Prophylaxis
12.5.2 Treatment
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 C-1 Esterase Inhibitors
13.4.2 Bradykynin Receptor Antagonist
13.4.3 Kallikrein Inhibitors
13.5 Historic and Forecasted Market Size By Application
13.5.1 Prophylaxis
13.5.2 Treatment
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 C-1 Esterase Inhibitors
14.4.2 Bradykynin Receptor Antagonist
14.4.3 Kallikrein Inhibitors
14.5 Historic and Forecasted Market Size By Application
14.5.1 Prophylaxis
14.5.2 Treatment
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Hereditary Angioedema Treatment Scope:
Report Data
|
Hereditary Angioedema Treatment Market
|
Hereditary Angioedema Treatment Market Size in 2025
|
USD XX million
|
Hereditary Angioedema Treatment CAGR 2025 - 2032
|
XX%
|
Hereditary Angioedema Treatment Base Year
|
2024
|
Hereditary Angioedema Treatment Forecast Data
|
2025 - 2032
|
Segments Covered
|
By Type, By Application, And by Regions
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
Key Companies Profiled
|
Pharming Group NV, CSL Behring, BIOCRYST PHARMACEUTICALS,INC, Attune Pharmaceuticals, Shire plc., Adverum, lonis Pharmaceuticals,Inc, Arrowhead Pharmaceuticals,Inc..
|
Key Segments
|
By Type
C-1 Esterase Inhibitors Bradykynin Receptor Antagonist Kallikrein Inhibitors
By Applications
Prophylaxis Treatment
|